DAYBUE: The First Approved Drug for Rett Syndrome Treatment
Rett syndrome is a rare genetic disorder that affects primarily females, with a reported incidence rate of approximately 1 in 10,000 to 15,000 live female births. This disorder affects the development of the brain and leads to severe intellectual and physical disability. Until recently, there were no approved treatments for Rett syndrome, but that has changed with the introduction of DAYBUE. Rett Syndrome Treatment Landscape The Rett syndrome treatment landscape has been limited, with few available options for patients. Most treatments have focused on symptom management, rather than addressing the underlying cause of the disorder. These treatments include physical therapy, speech therapy, and medication to manage seizures and other symptoms. Approval of DAYBUE: A Long-awaited Hope for Rett Syndrome Patients DAYBUE is the first and only approved drug for Rett syndrome treatment. The drug was approved by the FDA in August 2021, following promising clinical trial results. DAYBUE works b